UBS Downgrades Alkermes (ALKS) to Sell, 'Orexin pursuit risky, Lybalvi likely to stall'
Tweet Send to a Friend
UBS analyst Ashwani Verma downgraded Alkermes (NASDAQ: ALKS) from Neutral to Sell with a price target of $25.00.The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
